SCHEMBL2642467

SCHEMBL2642467

CS(=O)(=O)c1ccc([NH])cc1

nearest known ligand 0.56

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
ENPP2 Q13822 2/20 0.56
PTGS2 P35354 9/20 0.46
KIF11 P52732 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2376239 0.85 ENPP2 (0.72) ENPP2PTGS2
SCHEMBL487226 0.78 ENPP2 (0.56) ENPP2PTGS2
SCHEMBL10300269 0.77 PTGS2 (0.62) ENPP2PTGS2KIF11
SCHEMBL7677302 0.77 PTGS2 (0.62) ENPP2PTGS2KIF11
SCHEMBL17548700 0.77 ENPP2 (0.62) ENPP2PTGS2
Water SCHEMBL22687010 0.76 ENPP2 (0.54) ENPP2PTGS2
Water SCHEMBL28883186 0.76 ENPP2 (0.54) ENPP2PTGS2
SCHEMBL517832 0.74 ENPP2 (0.59) ENPP2PTGS2
SCHEMBL12807 0.74 GAA (0.65) ENPP2PTGS2
SCHEMBL28182477 0.74 GAA (0.65) ENPP2PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1957487-A1 NOVEL PYRIDOPYRAZINES AND THEIR USE AS MODULATORS OF KINASES AEterna Zentaris GmbH (DE) 2008-08-20 EP claimed
US-20070149484-A1 NOVEL PYRIDOPYRAZINES AND THEIR USE AS MODULATORS OF KINASES ZENTARIS GMBH (DE) 2007-06-28 US claimed
WO-2007054556-A1 NOVEL PYRIDOPYRAZINES AND THEIR USE AS MODULATORS OF KINASES ÆTERNA ZENTARIS GMBH (DE) 2007-05-18 WO claimed
EP-0073454-B1 6-ALPHA-METHOXY-PENICILLINS, THEIR SALTS, PROCESS FOR THEIR PREPARATION AND THERAPEUTIC AGENTS CONTAINING THESE COMPOUNDS Dr. Karl Thomae GmbH (DE) 1985-05-02 EP claimed
US-4454128-A ANTIBIOTICS DR. KARL THOMAE GMBH (DE) 1984-06-12 US claimed
EP-0035161-B1 CEPHALOSPORINS, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS Dr. Karl Thomae GmbH (DE) 1983-11-23 EP claimed
EP-0073454-A2 6-Alpha-methoxy-penicillins, their salts, process for their preparation and therapeutic agents containing these compounds Dr. Karl Thomae GmbH (DE) 1983-03-09 EP claimed
US-4370327-A Cephalosporins and pharmaceutical compositions BOEHRINGER INGELHEIM GMBH (DE) 1983-01-25 US claimed
EP-0035161-A2 Cephalosporins, processes for their preparation and pharmaceutical compositions containing these compounds Dr. Karl Thomae GmbH (DE) 1981-09-09 EP claimed
US-8765789-B2 2-pyridinecarboxamide derivatives MSD K.K. (JP) 2014-07-01 US disclosed
US-20130157976-A1 NOVEL PYRIDOPYRAZINES AND THEIR USE AS MODULATORS OF KINASES CLAUS ECKHARD (DE) 2013-06-20 US disclosed
US-20130085156-A1 NOVEL 2-PYRIDINECARBOXAMIDE DERIVATIVES MSD K.K. (JP) 2013-04-04 US disclosed
US-8344003-B2 2-pyridinecarboxamide derivatives MSD K. K. (JP) 2013-01-01 US disclosed
US-20120252760-A1 NOVEL PYRIDOPYRAZINES AND THEIR USE AS MODULATORS OF KINASES ZENTARIS GMBH (DE) 2012-10-04 US disclosed
EP-0418743-A2 Heat-developable light-sensitive material FUJI PHOTO FILM CO., LTD. (JP) 1991-03-27 EP disclosed
EP-0073454-B1 6-ALPHA-METHOXY-PENICILLINS, THEIR SALTS, PROCESS FOR THEIR PREPARATION AND THERAPEUTIC AGENTS CONTAINING THESE COMPOUNDS Dr. Karl Thomae GmbH (DE) 1985-05-02 EP disclosed
US-4454128-A ANTIBIOTICS DR. KARL THOMAE GMBH (DE) 1984-06-12 US disclosed
EP-0035161-B1 CEPHALOSPORINS, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS Dr. Karl Thomae GmbH (DE) 1983-11-23 EP disclosed
US-4370327-A Cephalosporins and pharmaceutical compositions BOEHRINGER INGELHEIM GMBH (DE) 1983-01-25 US disclosed
EP-0035161-A2 Cephalosporins, processes for their preparation and pharmaceutical compositions containing these compounds Dr. Karl Thomae GmbH (DE) 1981-09-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070149484-A1 NOVEL PYRIDOPYRAZINES AND THEIR USE AS MODULATORS OF KINASES MAP4K2, MAP3K15, MAP3K5 ENPP2 770/4885PTGS2 1036/4885KIF11 1584/4885
US-20120252760-A1 NOVEL PYRIDOPYRAZINES AND THEIR USE AS MODULATORS OF KINASES MAP4K2, MAP3K15, MAP3K5 ENPP2 770/4885PTGS2 1036/4885KIF11 1584/4885
US-20130085156-A1 NOVEL 2-PYRIDINECARBOXAMIDE DERIVATIVES GCKR, GCK, HK2 ENPP2 1848/4885PTGS2 1350/4885KIF11 3957/4885
US-20130157976-A1 NOVEL PYRIDOPYRAZINES AND THEIR USE AS MODULATORS OF KINASES MAP4K2, MAP3K15, MAP3K5 ENPP2 770/4885PTGS2 1036/4885KIF11 1584/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.